media – Page 157 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

Altman’s biotech company is raising $1 billion to extend human life by 10 years

San Francisco biotech company Retro Biosciences is raising $1 billion to support its mission to extend human life by 10 years through artificial intelligence (AI) technology. The company plans to advance its first drug to clinical trials this year. Retro Biosciences’ seed funding was provided by OpenAI CEO Sam Altman, with an amount of $180 million, and Altman will also invest additional funds in this round of Series A financing. The company is currently in talks with family offices, venture capital institutions, sovereign wealth funds, and a US “hyperscale” data center, which will provide it with the computing power needed to run AI models to accelerate drug development and testing. Retro Biosciences has developed a custom AI model in collaboration with OpenAI that can design proteins to temporarily convert ordinary cells into stem cells, thereby reversing the cellular aging process. The company plans to use the financing to fund clinical ...
- Source: drugdu
- 597
- February 1, 2025
The results of the selection of over 70 types of consumables for centralized procurement are about to be implemented

In 2024, the improvement of quality and expansion of consumables through centralized procurement will accelerate, and multiple high-value consumables will achieve significant price reductions; At the same time, the coverage of centralized procurement of in vitro diagnostic reagents is expanding, and the IVD industry is undergoing a comprehensive transformation. According to the statistics of Yaozhi Medical Equipment, about 10 large-scale consumables procurement projects were carried out in 2024, involving various types of consumables such as cochlear implants, peripheral interventions, IVD reagents, etc., and many varieties have not experienced centralized procurement and price reduction before. High value consumables, centralized procurement acceleration In 2024, the storm of centralized procurement in the high-value consumables field has not stopped, and multiple consumables have achieved significant price reductions. Among them, the results of centralized procurement of consumables in the intervention field are particularly significant. In the fifth batch of high-value consumables for national procurement, the ...
- Source: drugdu
- 268
- January 31, 2025
Two innovative medical devices have been approved for market launch

On January 20th, the National Medical Products Administration approved the registration applications for Xinuopu Medical Technology (Beijing) Co., Ltd.’s “Cryoablation Device” and Wuhan Kaidewis Biotechnology Co., Ltd.’s “Human CDO1/AJAP1/GALR1 Gene Methylation Detection Kit (Fluorescent PCR Method)”, two innovative products. Xinnopu Medical specializes in the field of electrophysiology Xinnopu Medical, founded in 2005, has been focusing on the field of cardiac electrophysiology for nearly 20 years and continues to lead industry technological innovation. It is a leader in the Chinese atrial septal puncture market. At present, Xinnopu Medical’s existing products cover dozens of categories including atrial septal puncture instruments, diagnostic instruments, and therapeutic instruments, and have established a complete business system covering research and development, manufacturing, and sales. Xinnopu Medical is actively promoting revolutionary innovation projects such as cryoablation system (Nordica), 3D mapping system (Meridian), intracardiac ultrasound (ICE) diagnostic catheter and equipment (enVision) with the innovation research and development center in ...
- Source: drugdu
- 215
- January 31, 2025
Si Longlong’s team develops a new strategy for attenuated live vaccines based on PROTAC

Influenza is a common respiratory infectious disease that spreads rapidly and is prone to mutation. According to statistics from the World Health Organization (WHO), there are approximately 1 billion cases of seasonal influenza worldwide each year. Vaccination is one of the most economical and effective means of preventing and controlling influenza. On January 15, 2025, Si Longlong’s team from the Institute of Synthetic Biology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, published two important research results in the two top international journals Nature Microbiology and Nature Chemical Biology at the same time, providing a new idea for the development of influenza vaccines. Breakthrough 1: Constructing a PROTAR influenza vaccine library to expand vaccine diversity Traditional vaccines have poor immune effects and safety risks when facing frequent virus mutations, and the development cycle is long and complicated. In 2022, Si Longlong’s team pioneered the PROTAR attenuated live vaccine technology, ...
- Source: drugdu
- 308
- January 31, 2025
【EXPERT Q&A】What certifications are required for pharmaceutical exports to Saudi Arabia?

Drugdu.com expert’s response: For the export of pharmaceuticals to Saudi Arabia, the following certifications are mandatory: I. SFDA Certification Definition: SFDA certification refers to the certification of the Saudi Food and Drug Authority (SFDA). SFDA is responsible for regulating and managing the safety, quality, and effectiveness of products such as food, drugs, medical devices, and cosmetics to safeguard public health and safety. Importance: SFDA certification is essential for selling pharmaceutical products in the Saudi market. Products without SFDA certification cannot be legally sold. Only after obtaining SFDA certification can products be legally sold and used in the Saudi Arabian market. Application Process: Prepare product descriptions, technical specifications, manufacturing processes, quality management system documents, etc., for submission of the SFDA certification application. Select a qualified certification body (usually a third-party organization) to conduct product testing and evaluation, ensuring that the body has the appropriate experience and qualifications in SFDA certification. Submit ...
- Source: drugdu
- 407
- January 31, 2025
Baili Tianheng’s revenue is expected to increase by 932%

On January 21, Baili Tianheng released its 2024 performance forecast, expecting to achieve annual operating income of approximately 5.8 billion yuan, a year-on-year increase of 932.27%; the net profit attributable to the parent company’s owners is expected to be 3.6 billion yuan, an increase of 4.38 billion yuan from the same period last year, and will turn losses into profits. The notice disclosed that this significant performance growth was mainly due to the irrevocable, non-deductible down payment of US$800 million paid by the company’s overseas partner Bristol-Myers Squibb (BMS) for its core product BL-B01D1 during the reporting period, which led to a significant increase in the company’s operating income. BL-B01D1 is a dual-antibody ADC targeting EGFR×HER3. It is the world’s first and only drug of its kind to enter the clinical stage. At the end of 2023, SystImmune, a wholly-owned subsidiary of Baili Tianheng, reached an exclusive licensing and cooperation ...
- Source: drugdu
- 301
- January 30, 2025
Promoting the “going out” of medicines, my country opens up the “next stop” of medicine centralized procurement for ASEAN

At present, my country’s medical security has entered a new stage of high-quality development with rapid expansion, deepening reform and continuous innovation. It has carried out 10 batches of national organized drug centralized procurement and 5 batches of national organized high-value medical consumables centralized procurement, including a total of 435 kinds of drugs, and commonly used high-value medical consumables cover cardiology, orthopedics, etc. At the beginning of 2025, my country’s medicine centralized procurement ushered in a new opportunity to “go out”. Recently, the China-ASEAN Regional Medicine Centralized Procurement Platform was officially launched in Fangchenggang City, Guangxi. It is the first cross-border medicine regional centralized procurement platform guided by the National Medical Security Administration. Build an open pharmaceutical procurement cooperation platform According to reports, the China-ASEAN Regional Pharmaceutical Procurement Platform is responsible for carrying out joint procurement in some regions of China and ASEAN countries. It will explore innovative regional medical, ...
- Source: drugdu
- 415
- January 30, 2025
Application for registration and marketing authorization of quadrivalent influenza vaccine has been accepted

Chengda Bio announced in the evening that the application for registration and marketing authorization of the quadrivalent influenza virus split vaccine (referred to as “quadrivalent influenza vaccine”) developed by its wholly-owned subsidiary Chengda Bio (Benxi) Co., Ltd. in China has recently received the “Acceptance Notice” from the State Food and Drug Administration. https://finance.eastmoney.com/
- Source: drugdu
- 235
- January 30, 2025
Fosun Pharma’s drug registration application for salbutamol hydrochloride has been accepted

On January 24, Fosun Pharma (600196/02196) issued an announcement that the drug registration application for salbutamol hydrochloride nebulized inhalation solution of its holding subsidiary Fosun Pharma (Xuzhou) Co., Ltd. was recently accepted by the State Drug Administration. The drug is a chemical drug independently developed by the company, mainly used to treat or prevent bronchospasm caused by reversible airway obstructive diseases in adults and children over 6 years old. As of December 2024, the group’s cumulative R&D investment in the drug is approximately 4.54 million yuan. According to data provided by IQVIA, the sales of salbutamol hydrochloride nebulized inhalation solution in China in 2023 will be approximately 1.009 billion yuan. The announcement pointed out that the drug still needs to pass GMP compliance inspection and obtain drug registration approval before commercial production, so the acceptance of the drug registration application will not have a significant impact on the group’s current ...
- Source: drugdu
- 220
- January 30, 2025
encourage and support pharmaceutical operators to strengthen anti-monopoly compliance

On January 24, in order to effectively prevent and stop monopoly behavior in the pharmaceutical sector and safeguard consumer interests and social public interests, the State Council Anti-monopoly and Anti-unfair Competition Committee formulated and issued the “Anti-monopoly Guidelines for the Pharmaceutical Sector” (hereinafter referred to as the “Guidelines”). The “Guidelines” have 7 chapters and 55 articles. Aiming at the prominent monopoly problems in the pharmaceutical sector, they further refine the behavior, law enforcement principles and identification standards of monopoly behavior in the pharmaceutical sector. The “Guidelines” refine the behavior of monopoly agreements in the pharmaceutical sector. First, they list typical horizontal and vertical monopoly agreements in the pharmaceutical sector, and clarify the identification principles and ideas of anti-monopoly law enforcement agencies; Second, they summarize the behavior of new monopoly agreements in the pharmaceutical sector, and summarize the considerations for the application of the “Anti-monopoly Law” to reverse payment agreements; Third, ...
- Source: drugdu
- 282
- January 30, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.